Submit Manuscript  

Article Details

Drug Repositioning: A Smart Approach for Combating SARS-CoV-2


Supriya Roy and Suneela Dhaneshwar*   Pages 1 - 21 ( 21 )


The enigmatic coronavirus outburst on December 31, 2019, originated from Wuhan city of China, is now declared as Coronavirus disease (COVID-19) by World Health Organization (WHO). The causative agent is highly contagious, and its rapid blowout affects almost every country of the world, endangering thousands of lives. Recently, WHO has raised the COVID-19 epidemic threat to the "very high" level. Pathophysiological mechanisms are related to the interrelated functioning of various viral polyproteins, structural proteins as well as non-structural proteins (NSP). These proteins play a crucial role in accelerating pathogenesis by promoting viral replication, viral assembly, and virion release thereby disabling the overall host distinctive immunological system. Presently, there is no specific treatment for COVID-19. Majority of the treatments focus on symptomatic relief and supportive therapy only. Although several drugs have been investigated against coronavirus in numerous clinical trials, only a few exhibited mild-moderate signs of clinical recovery. Drugs that are being repurposed and researched involve an anti-malarial drug, hydroxychloroquine; anti-HIV drugs, lopinavir, Remdesivir alone, or in combination; anti-influenza drugs like umifenovir, favilavir; anti-arthritic baracitinib, and antiinterleukins. Various research articles demonstrated the excellent potential of hydroxychloroquine either alone or in combination with anti-HIV drugs lopinavir, Remdesivir at the cellular level, however exhaustive clinical support and validation are still desirable for repurposing these drugs. Profound identification of cellular targets involved in disease pathogenesis may warrant successful re-profiling of the candidate drugs or their combinations aiming against COVID-19.


Coronavirus, SARS-CoV-2, drug repurposing, pandemic, vaccines, convalescent plasma therapy, lopinavir, Remdesivir, antiretrovirals, clinical trials.


Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, Lucknow

Read Full-Text article